Novo Nordisk’s drugs are being linked to an eye condition that can cause vision loss, while health tech companies made CNBC’s ...

Don’t be persuaded by the abundance of propaganda you see in ads, newspapers, magazines, TV, and the Internet. There is no ...

Many folks in NC can’t access Ozempic due to limited insurance coverage. But policy changes and falling prices may expand ...

They have been called miraculous and the fastest way to lose weight. From Wegovy to Mounjaro, here’s how GLP-1 drugs work ...

Novo Nordisk NVO and Viking Therapeutics VKTX have emerged as notable players in the obesity space. A market leader in the GLP-1 space, Novo Nordisk markets its semaglutide drugs under brand names ...

March is National Kidney Month – a time to raise awareness and learn more about kidney health and kidney disease ... Novo Nordisk manufactures FDA-approved semaglutide medicines, like Ozempic®.

New York, USA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Novo Nordisk’s OZEMPIC Approval Heat Up the Chronic Kidney Disease Therapeutic Market | DelveInsight The FDA’s recent approval of OZEMPIC ...

EXTON, PA, Feb. 05, 2025 (GLOBE NEWSWIRE) -- As chronic kidney disease (CKD ... the FDA’s recent label expansion of Novo Nordisk’s Ozempic® to include CKD benefits, reinforcing the drug ...

EXTON, PA, Feb. 05, 2025 (GLOBE NEWSWIRE) -- As chronic kidney disease (CKD ... the FDA’s recent label expansion of Novo Nordisk’s Ozempic® to include CKD benefits, reinforcing the drug ...

Semaglutide reduced the risk of kidney disease worsening ... Medical & Regulatory Affairs at Novo Nordisk. Ozempic is also indicated as an adjunct to diet and exercise to improve glycemic control ...

Ozempic, the GLP-1 drug initially ... was recently OK’d to help reduce risks linked to chronic kidney disease (CKD). That’s according to Novo Nordisk, a pharmaceutical company and maker ...

"Chronic kidney disease is very serious and common ... medical & regulatory affairs for Novo Nordisk, maker of Ozempic — in a press release. “This approval for Ozempic allows us to more ...